NASDAQ: VAXX - Vaxxinity, Inc.

Rentabilidad a seis meses: -99.93%
Sector: Healthcare

Calendario de promoción Vaxxinity, Inc.

Horario avanzado gráfico sencillo
Financial Markets by TradingView

Acerca de la empresa

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States.

más detalles
The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.
Añadir a la lista de comparación
Añadir a la lista de vigilancia
Añadir al portafolio
Añadir aviso de precio

IPO date 2021-11-11
ISIN US92244V1044
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.vaxxinity.com
Цена ао 0.65
Cambio de precio por día: -33.33% (0.0003)
Cambio de precio por semana.: -33.33% (0.0003)
Cambio de precio por mes: +100% (0.0001)
Cambio de precio en 3 meses.: -99% (0.02)
Cambio de precio en seis meses: -99.93% (0.2739)
Cambio de precio por año: -99.98% (0.85)
Cambio de precio en 3 años.: -100% (6.56)
Cambio de precio en 5 años.: 0% (0.0002)
Cambio de precio en 10 años.: 0% (0.0002)
Cambio de precio desde principios de año.: +100% (0.0001)
Todos los parámetros

Subestimación

Nombre Significado Calificación
P/S 0 0
P/BV 9.72 1
P/E 0 0
EV/EBITDA -2.51 0
Total: 2.63

Eficiencia

Nombre Significado Calificación
ROA, % -128.37 0
ROE, % -424.6 0
Total: 0

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0

Deber

Nombre Significado Calificación
Debt/EBITDA -0.2706 10
Total: 9.6

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % -100.18 0
Rentabilidad Ebitda, % -99.59 0
Rentabilidad EPS, % 294.77 10
Total: 4
Más detalles

Instituciones Volumen Compartir, %
Prime Movers Lab, LLC 15744167 13.95
Adage Capital Partners GP L.L.C. 3000000 2.66
Blackrock Inc. 2526951 2.24
Vanguard Group Inc 2377385 2.11
State Street Corporation 832473 0.74
Geode Capital Management, LLC 829802 0.74
Bank of America Corporation 499557 0.44
Northern Trust Corporation 351812 0.31
Creative Planning 278646 0.25
Pathstone Family Office, LLC 153846 0.14



Supervisor Título profesional Pago año de nacimiento
Mr. Louis Garfield Reese IV Co-Founder & Executive Chairman of the Board 83.28k 1982 (43 año)
Ms. Mei Mei Hu J.D. Co-Founder, President, CEO & Director 551.73k 1983 (42 año)
Mr. Jason Pesile CPA, M.B.A. Chief Accounting Officer N/A 1973 (52 año)
Ms. Sumita Ray J.D. Chief Legal, Compliance & Administrative Officer and Corporate Secretary N/A 1974 (51 año)
Mr. Mark Joinnides MSE Chief of Staff N/A
Dr. Jean-Cosme Dodart Ph.D. Chief Scientific Officer N/A
Dr. Manal Morsy M.B.A., M.D., PH.D. Chief Regulatory Officer

DIRECCIÓN: United States, Merritt Island. FL, 505 Odyssey Way - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.vaxxinity.com